✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Cellobiose is an investigational drug.
There have been 5 clinical trials for Cellobiose. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2012.
The most common disease conditions in clinical trials are Pulmonary Disease, Chronic Obstructive, Lung Diseases, and Chronic Disease. The leading clinical trial sponsors are GlaxoSmithKline, Federico II University, and [disabled in preview].
There are five hundred and twenty-seven US patents protecting this investigational drug and twenty-five international patents.
Recent Clinical Trials for Cellobiose
|A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pedi||Federico II University||Phase 4|
|A Study to Assess the Safety and Tolerability of Once Daily Inhaled Doses of GSK573719 Made With Magnesium Stearate in Subjects With Chronic Obstructive Pulmonary Disease(COPD)for 7 Days||GlaxoSmithKline||Phase 2|
|A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In COPD Patients.||GlaxoSmithKline||Phase 2|
Top disease conditions for Cellobiose
Top clinical trial sponsors for Cellobiose
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Cellobiose||See Plans and Pricing||Polypeptides having beta-xylosidase activity and polynucleotides encoding same||Novozymes, Inc. (Davis, CA)||See Plans and Pricing|
|Cellobiose||See Plans and Pricing||Inhalable pharmaceutical compositions||iCeutica Pty Ltd. (Iluka, WA, AU)||See Plans and Pricing|
|Cellobiose||See Plans and Pricing||Polymeric nanoparticles and methods of making and using same||Merck Sharp & Dohme Corp. (Rahway, NJ) Pfizer Inc. (New York, NY)||See Plans and Pricing|
|Cellobiose||See Plans and Pricing||Aerosol pirfenidone and pyridone analog compounds and uses thereof||AVALYN PHARMA INC. (Seattle, CA)||See Plans and Pricing|
|Cellobiose||See Plans and Pricing||Human anti-IL-23 antibodies, compositions, methods and uses||Janssen Biotech, Inc. (Horsham, PA)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Cellobiose||European Patent Office||EP2875139||2032-07-23||See Plans and Pricing|
|Cellobiose||United Kingdom||GB201213032||2032-07-23||See Plans and Pricing|
|Cellobiose||United Kingdom||GB2505638||2032-07-23||See Plans and Pricing|
|Cellobiose||World Intellectual Property Organization (WIPO)||WO2014016576||2032-07-23||See Plans and Pricing|
|Cellobiose||Brazil||BR112016011608||2033-11-22||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|